Month: March 2022

Topline data from Phase 2b ASPEN-COVID-19 clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the last week of March 2022 WESTMINSTER, Colo., March 14, 2022 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2021 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “We have completed blinded data collection from the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19 and look forward to unblinding and subsequently reporting results of the study in the last week of this month. We believe rNAPc2 has the potential...

Announced strategic reprioritization, with plans to advance mucopolysaccharidosis type I (MPS-1) and diabetes as lead indications as well as continued platform optimization Strengthened leadership team with appointment of new Chief Technical Operations Officer and other key leadership changes Current cash position expected to fund operating plans into 2024 CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the fourth quarter and full year ended December 31, 2021 as well as certain other business highlights. “In 2021, we made important adjustments to our overall corporate and clinical strategy as well as our leadership...

Atlanta, March 14, 2022 (GLOBE NEWSWIRE) — Acuity Brands, Inc. (NYSE: AYI) (“Company”) today announced that the Company is planning to release its fiscal 2022 second-quarter earnings results on Tuesday, April 5, at 6:00 a.m. (EDT) to be followed by a conference call at 8:00 a.m. (EDT).  Neil Ashe, Chairman, President and Chief Executive Officer of Acuity Brands, will lead the call.   The conference call and earnings release can be accessed via the Investor Relations section of the Company’s website at investors.acuitybrands.com. The online replay will remain available for a limited time following the call. A replay of the call will also be posted to the Investor Relations site within two hours of the completion of the conference call and will be archived on the site.   To learn more about Acuity Brands, please visit the Company’s website....

Continues to Consolidate Portfolio Through Attractive Buy-Outs of JV Partners GREAT NECK, N.Y., March 14, 2022 (GLOBE NEWSWIRE) — BRT APARTMENTS CORP. (NYSE:BRT), a real estate investment trust that owns, operates and, to a lesser extent, develops multi-family properties, today reported that for the three months ended December 31, 2021, it generated a net loss of $1.25 million, or $0.08 per diluted share, FFO1 of $6.3 million, or $0.35 per diluted share, and AFFO of $7.5 million, or $0.41 per diluted share, and that for the twelve months ended December 31, 2021, it generated net income of $29.1 million, or $1.62 per diluted share, FFO of $17.43 million, or $0.97 per diluted share, and AFFO of $23.81 million, or $1.33 per diluted share. Jeffrey A. Gould, President and Chief Executive Officer of BRT stated, “Our portfolio continued...

Second quarter revenue of $34.0 million increased 28% sequentially and 8% year-over-year compared to FY2021 Enzo Biochem posted highest quarterly revenue in history of the Company Enzo Life Science revenue reached $10.4 million, an increase of 39% year over year Received LDT regulatory approval from New York State for CT/NG/TV molecular tests Q2 FY22 product margin increased to 49% compared to 40% in Q1 FY22 and 47% Q2 FY21 CEO advances strategy to focus on core competencies while strengthening and augmenting management teamConference call and live webcast scheduled for today,Monday, March 14, 2022 at 4:30 pm (ET) NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) — Enzo Biochem, Inc (NYSE: ENZ), a leading biosciences and diagnostics company, today reported financial results for the second quarter ended January 31, 2022 and provided...

AUSTIN, March 14, 2022 (GLOBE NEWSWIRE) — Asure Software, Inc. (Nasdaq: ASUR), a leading provider of cloud-based Human Capital Management (“HCM”) software solutions, reported results for the fourth quarter and year ended December 31, 2021. “Our fourth quarter and full year results show the many benefits of our growth strategy,” said Chairman and CEO, Pat Goepel. “We continue to execute determinedly on the key priorities that we believe will drive future revenues and value creation. These priorities include a resolute focus on enhancing organic revenue growth, on executing acquisitions in our core target markets to build scale and profitability, on investments in sales and marketing to drive future revenue and on product and platform innovations that add value for our customers. Our strategy drove 29% annual growth in revenues...

Q4 2021 revenue $16.2 million and FY 2021 revenue $54.9 millionFY 2022 revenue guidance $69 – 71 million MARLBOROUGH, Mass., March 14, 2022 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2021. “Our strong finish to 2021 demonstrates the continued and accelerating adoption of our leading spatial biology solutions and is a result of sound execution of our financial and strategic plans,” said Brian McKelligon, Chief Executive Officer, Akoya Biosciences.  “We set another record in quarterly revenue, grew our installed base to nearly 700 instruments worldwide, and have approximately 500 publications on Akoya platforms to date. Highlighting our strong quarter was the commercial launch...

Expecting Saturn-2 Phase 3 topline data in April 2022, the second pivotal of TP-03 for the treatment of Demodex blepharitis, and NDA submission this year Advancing pipeline this year with planned Phase 2 initiations of TP-03 for Meibomian Gland Disease and TP-04 for Rosacea, and TP-05 Phase 1b data for Lyme disease prevention Anticipated cash runway into at least the second half of 2024, inclusive of $171 million of cash as of December 31, 2021, expected milestones from China out-license, and credit facility availability IRVINE, Calif., March 14, 2022 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the full-year ended December...

NEWTOWN, Pa., March 14, 2022 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter and full year ended December 31, 2021. Fourth Quarter and Recent Business UpdatesU.S. commercial launch of PoNS® for multiple sclerosis (“MS”) progressed with first prescriptions received this month. Received marketing authorization in Australia for sale of PoNS as a Class IIa medical device to improve balance and gait. Launched partnership with Medical University of South Carolina for collaborative clinical trial on stroke, allowing for observation of PoNS therapy in a real-world clinical setting. Partnered with NYU Langone Health as the first clinical trial site for the Company-sponsored Therapeutic...

Quarterly revenue of $77.8 million, up 69% year-over-yearStrong Dollar-Based Net Retention Rate at over 152% Fiscal Fourth Quarter Highlights:Total revenue of $77.8 million GAAP operating margin of (52)%; Non-GAAP operating margin of (35)% GAAP net loss per share of $(0.32); Non-GAAP net loss per share of $(0.16)Fiscal Year 2022 Highlights:Total revenue of $252.7 million GAAP operating margin of (51)%; Non-GAAP operating margin of (39)% GAAP net loss per share of $(1.95); Non-GAAP net loss per share of $(1.20)SAN FRANCISCO, March 14, 2022 (GLOBE NEWSWIRE) — All-Remote — GitLab Inc. (NASDAQ: GTLB), The DevOps Platform, today reported financial results for its fourth quarter and full year of fiscal 2022, ended January 31, 2022. “We are seeing continued strong momentum for customers adopting our DevOps platform, as revenue...